findmyKOL
Clinical trialNCT06832865RecruitingPhase 2Interventional

ELISA in Relapsed/Refractory MM

SponsorMassachusetts General HospitalEnrollment30Relapsed Refractory Multiple MyelomaRelapsed Refractory Multiple Myeloma (RRMM)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior lines of therapy and who have had previous treatment with both immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI). The subcutaneous injection method of isatuximab administration, including the device used to administer isatuximab, is investigational.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, United States

    David Avigan, MD
    Recruiting
  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

    Shonali Midha, MD
    Not, yet, recruiting
  • Massachusetts General Hospital

    Boston, Massachusetts, United States

    Noopur Raje, MD →
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Isatuximab →Elranatamab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
14 Aug 2025
Primary completion
1 Dec 2026
Completion
1 Dec 2028
Last update posted
12 Mar 2026
Registered enrollment
30
Registry id
NCT06832865
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.